Scott Zari says investors can avoid the Trump administration's pharmaceutical tariffs by looking to companies that are already domestically manufacturing drugs and medicine like Eli Lilly (LLY). Compared to other drugmakers that have dipped into the weight-loss market, Scott says injectables will continue to be the primary use case saying pills haven't yet overtaken it. He looks at other drugmakers like Pfizer (PFE) and Novo Nordisk (NVO).